Production (Stage)
Avenue Therapeutics, Inc.
ATXI
$0.2088
-$0.0113-5.13%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 44.91% | 24.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 19.36% | -49.43% | |||
| Operating Income | -19.36% | 49.43% | |||
| Income Before Tax | -19.18% | 49.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -19.18% | 49.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -60.00% | 36.36% | |||
| Net Income | -19.95% | 49.80% | |||
| EBIT | -19.36% | 49.43% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -116.26% | 299.43% | |||
| Normalized Basic EPS | 23.17% | 57.77% | |||
| EPS Diluted | -116.26% | 299.43% | |||
| Normalized Diluted EPS | 23.17% | 57.77% | |||
| Average Basic Shares Outstanding | 56.75% | 18.44% | |||
| Average Diluted Shares Outstanding | 56.75% | 18.44% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||